SEC Form SC 13G/A filed by Apyx Medical Corporation (Amendment)

2/14/24 5:06:24 PM ET

Medical/Dental Instruments

Health Care

Get the next $APYX alert in real time by email

SC 13G/A 1 apyx13g.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2)* APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ X ] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 03837C106 13G Page 2 of 7 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Pura Vida Investments, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 80,000* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 80,000* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 80,000* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.23%** 12. TYPE OF REPORTING PERSON (see instructions) IA CUSIP No. 03837C106 13G Page 3 of 7 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Efrem Kamen 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 80,000* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 80,000* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 80,000* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.23%** 12. TYPE OF REPORTING PERSON (see instructions) IN, HC CUSIP No. 03837C106 13G Page 4 of 7 Pages Item 1. (a) Name of Issuer APYX MEDICAL CORPORATION (b) Address of Issuers Principal Executive Offices 5115 Ulmerton Road, Clearwater, FL 33760 Item 2. (a) Name of Person Filing Pura Vida Investments, LLC Efrem Kamen (collectively, the "Reporting Persons"). (b) The address of the principal place of the Reporting Persons is located at: Pura Vida Investments, LLC 545 West 25th Street, 19th Floor New York, NY 10001 (c) For citizenship of the Reporting Persons, see Item 4 of the cover sheet for each Reporting Person. (d) Title of Class of Securities Common Stock, $0.001 par value per share (e) CUSIP Number 03837C106 Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [x] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). CUSIP No. 03837C106 13G Page 5 of 7 Pages Item 4. Ownership. (a) Amount beneficially owned: Pura Vida Investments LLC 80,000* shares Efrem Kamen 80,000* shares (b) Percent of class: Pura Vida Investments LLC 0.23%** Efrem Kamen 0.23%** (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: Pura Vida Investments LLC 80,000* shares Efrem Kamen 80,000* shares (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: Pura Vida Investments, LLC 80,000* shares Efrem Kamen 80,000* shares *Shares reported herein are owned by Pura Vida Master Fund, Ltd (the "Pura Vida Master Fund) and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the shares owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of the Reporting Persons pecuniary interest therein, if any. **The percentages herein are calculated based upon 34,643,855 shares of Common Stock of the Issuer outstanding as of November 16, 2023, per the Issuers Form S-8 filed with the Securities and Exchange Commission on November 16, 2023. CUSIP No. 03837C106 13G Page 6 of 7 Pages Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ]. Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Exhibits. Exhibit A Joint Filing Agreement. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 14, 2024 Pura Vida Investments, LLC By: /s/ Efrem Kamen, Managing Member CUSIP No. 03837C106 13G Page 7 of 7 Pages EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases and sales by the undersigned of the securities of any issuer until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. For that purpose, the undersigned hereby constitute and appoint Pura Vida Investments, LLC, a limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases and sales, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present, until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. Dated: February 14, 2024 Pura Vida Investments, LLC By: /s/ Efrem Kamen, Managing Member

Get the next $APYX alert in real time by email

Date

Price Target

Rating

Analyst

10/17/2024

Neutral

BTIG Research

7/14/2023

$8.00

Overweight

Stephens

5/20/2022

$12.00

Buy

Lake Street

8/13/2021

$12.00 → $14.00

Market Outperform

JMP Securities

SEC Form SC 13G/A filed by Apyx Medical Corporation (Amendment)

Chat with this insight

Recent Analyst Ratings for $APYX

$APYX Financials

Live finance-specific insights

Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024

Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook

$APYX Press Releases

Fastest customizable press release news feed in the world

Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener"

Apyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

$APYX Leadership Updates

Live Leadership Updates

Apyx Medical Corporation Announces Board Leadership Transition

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

$APYX SEC Filings

$APYX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$APYX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 10-K filed by Apyx Medical Corporation

Apyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Apyx Medical Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

Amendment: Chief Financial Officer Hill Matthew C bought $6,780 worth of shares (6,000 units at $1.13), increasing direct ownership by 240% to 8,500 units (SEC Form 4)

Chief Financial Officer Hill Matthew C bought $6,030 worth of shares (5,336 units at $1.13), increasing direct ownership by 213% to 7,836 units (SEC Form 4)

Hill Matthew C bought $5,475 worth of shares (2,500 units at $2.19) (SEC Form 4)

Amendment: Chief Financial Officer Hill Matthew C bought $6,780 worth of shares (6,000 units at $1.13), increasing direct ownership by 240% to 8,500 units (SEC Form 4)

SEC Form 4 filed by Chief Operating Officer Roman Shawn David

SEC Form 4 filed by Director Baylor-Henry Minnie

$APYX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Apyx Medical Corporation

Amendment: SEC Form SC 13G/A filed by Apyx Medical Corporation

SEC Form SC 13D/A filed by Apyx Medical Corporation (Amendment)

$APYX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BTIG Research initiated coverage on Apyx Medical

Stephens initiated coverage on Apyx Medical with a new price target

Lake Street initiated coverage on Apyx Medical with a new price target

Recent Analyst Ratings for
$APYX

$APYX
Financials

$APYX
Press Releases

$APYX
Leadership Updates

$APYX
SEC Filings

$APYX
Insider Purchases

$APYX
Insider Trading

$APYX
Large Ownership Changes

$APYX
Analyst Ratings